Short Chain Fatty Acids

Prophylactic Role of Aloe Components, Butyrate Fermented, Micrnas, and Hyaluronan on Alzheimer’s Disease, Parkinson’s Disease, and Osteoarthritis in Knee Joints

Butyrate, Gut Dysbiosis, Gut-Brain axis, Metabolites, Probiotics, Prebiotics and Symbiotics, Short Chain Fatty Acids /

Host microbial cross talk is essential to maintain intestinal homeostasis. However, maladaptation of the response through microbial dysbiosis or defective host defense toward invasive intestinal microbial results in chronic inflammation and the mild cognitive impairment. The role of active constituents from Aloe species, fermented butyrate, and micRNAs on Alzheimer’s disease, and Parkinson’s disease is discussed […]

Prophylactic Role of Aloe Components, Butyrate Fermented, Micrnas, and Hyaluronan on Alzheimer’s Disease, Parkinson’s Disease, and Osteoarthritis in Knee Joints Read More »

Short-chain fatty acids in the context of Parkinson’s disease

A-Synuclein, Butyrate, Short Chain Fatty Acids /

Taken together, there is strong evidence that the gastrointestinal microbiome is altered in PD and this is similarly true for the composition of the intestinal metabolome. SCFAs are increasingly studied intestinal metabolites that have shown great potential to influence disease processes in neuroinflammatory disorders. Their role for neurodegenerative movement disorders such as PD is still

Short-chain fatty acids in the context of Parkinson’s disease Read More »

Effects of Resistant Starch on Symptoms, Fecal Markers and Gut Microbiota in Parkinson’s Disease – The RESISTA-PD Trial

Butyrate, Pre-PD, Probiotics, Prebiotics and Symbiotics, Short Chain Fatty Acids, Therapies /

Clinically, we observed a reduction in non-motor symptoms load in PD + RS. The reference-based analysis of metagenomes highlighted stable alpha-diversity and beta-diversity across the three groups, including bacteria producing SCFAs. Reference-free analysis suggested punctual, yet pronounced differences in the metagenomic signature in PD + RS. RESISTA-PD highlights that a prebiotic treatment with RS is

Effects of Resistant Starch on Symptoms, Fecal Markers and Gut Microbiota in Parkinson’s Disease – The RESISTA-PD Trial Read More »

Why Researchers Look to Gut Microbial Metabolites in Parkinson’s Disease

Gut Microbiota, Gut Permeability / Leaky Gut, Metabolites, Short Chain Fatty Acids, Symptoms / Diagnosis /

Findings highlight significant differences in the fecal microbiome and metabolome in patients with Parkinson’s disease and control subjects, demonstrating an important connection between the brain and gut that could influence the disease process and progression. CLICK TO REVIEW

Why Researchers Look to Gut Microbial Metabolites in Parkinson’s Disease Read More »

Prebiotic dietary fibre intervention improves fecal markers related to inflammation in obese patients: results from the Food4Gut randomized placebo-controlled trial

Diet and Exercise, Pre-PD, Probiotics, Prebiotics and Symbiotics, Short Chain Fatty Acids /

Our study demonstrates that ITF-prebiotic intake during 3 months decreases a fecal marker of intestinal inflammation in obese patients. Our data point to a potential contribution of microbial lipid-derived metabolites in gastro-intestinal dysfunction related to obesity. CLICK TO REVIEW

Prebiotic dietary fibre intervention improves fecal markers related to inflammation in obese patients: results from the Food4Gut randomized placebo-controlled trial Read More »

Advances of Mechanisms-Related Metabolomics in Parkinson’s Disease

Biomarkers, Butyrate, Diet and Exercise, Gut Dysbiosis, Gut Microbiota, Mitochondria, Pre-PD, Short Chain Fatty Acids /

In this review, we briefly summarize recent findings and analyze the application of molecular metabolomics in familial and sporadic PD from genetic mutations, mitochondrial dysfunction, and dysbacteriosis. We also review metabolic biomarkers to assess the functional stage and improve therapeutic strategies to postpone or hinder the disease progression. CLICK TO REVIEW

Advances of Mechanisms-Related Metabolomics in Parkinson’s Disease Read More »

Astaxanthin Alleviates Ochratoxin A-Induced Cecum Injury and Inflammation in Mice by Regulating the Diversity of Cecal Microbiota and TLR4/MyD88/NF-κB Signaling Pathway

Anti-oxidants, Butyrate, Short Chain Fatty Acids, Vitamins / Supplements / Nutraceuticals /

Ochratoxin A (OTA) is a common environmental pollutant found in a variety of foods and grains, and excessive OTA consumptioncauses serious global health effects on animals and humans. Astaxanthin (AST) is a natural carotenoid that has anti-inflammatory,antiapoptotic, immunomodulatory, antitumor, antidiabetes, and other biological activities. The present study is aimed atinvestigating the effects of AST on

Astaxanthin Alleviates Ochratoxin A-Induced Cecum Injury and Inflammation in Mice by Regulating the Diversity of Cecal Microbiota and TLR4/MyD88/NF-κB Signaling Pathway Read More »

Bacterial Metabolites Mirror Altered Gut Microbiota Composition in Patients with Parkinson’s Disease

Gut Microbiota, Short Chain Fatty Acids /

Increasing evidence is supporting the hypothesis of -synuclein pathology spreading from the gut to the brainalthough the exact etiology of Parkinson’s disease (PD) is unknown. Furthermore, it has been proposed that inflammation,via the gastrointestinal tract, potentially through infections, may contribute to -synuclein pathogenesis, and thus to the riskof developing PD. CLICK TO REVIEW

Bacterial Metabolites Mirror Altered Gut Microbiota Composition in Patients with Parkinson’s Disease Read More »